Geron Corporation To Host Analyst And Investor Meeting On December 8

MENLO PARK, Calif., December 5, 2014 - Geron Corporation (Nasdaq: GERN) today announced that management will be hosting a live webcast of an analyst and investor meeting at 7:00 p.m. PT on December 8, 2014. John A. Scarlett, M.D., Geron's President and Chief Executive Officer, will present a company overview and discuss data presented at the 56th American Society of Hematology (ASH) Annual Meeting. In addition, Steven Lane, M.D., an investigator at the Queensland Institute of Medical Research, will discuss his preclinical proof-of-concept data on imetelstat in acute myelogenous leukemia which was published in Cell Stem Cell as well as presented at the 56th ASH Annual Meeting. The audio and slide presentation can be accessed at http://edge.media-server.com/m/p/7gbsnwrt or www.geron.com on the Investor Relations pages, under Events. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.

About Geron

Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

Help employers find you! Check out all the jobs and post your resume.